[1] Cortes-Canteli M, Iadecola C. Alzheimer's disease and vascular aging: JACC focus seminar. J Am Coll Cardiol, 2020; 75, 942−51.
[2] Brent RJ. Behavioral versus biological definitions of dementia symptoms: recognizing that worthwhile interventions already exist. OBM Geriat, 2019; 3. doi:  10.21926/obm.geriatr.1904079
[3] Clare L, Kudlicka A, Oyebode JR, et al. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT. Health Technol Assess, 2019; 23, 1−242.
[4] das Nair R, Bradshaw LE, Carpenter H, et al. A group memory rehabilitation programme for people with traumatic brain injuries: the ReMemBrIn RCT. Health Technol Assess, 2019; 23, 1−194.
[5] Zhang S, Huang SY, An XB, et al. Medical histories of control subjects influence the biomarker potential of plasma Aβ in Alzheimer's disease: a meta-analysis. J Mol Neurosci. 2020 Mar 3. doi: 10.1007/s12031-020-01510-1.[Epubaheadofprint]
[6] Mantzavinos V, Alexiou A. Biomarkers for Alzheimer's disease diagnosis. Curr Alzheimer Res, 2017; 14, 1149−54.
[7] Karlawish J, Jack CR Jr, Rocca WA, et al. Alzheimer's disease: the next frontier-special report 2017. Alzheimers Dement, 2017; 13, 374−80. doi:  10.1016/j.jalz.2017.02.006
[8] Atri A. The Alzheimer's disease clinical spectrum: diagnosis and management. Med Clin North Am, 2019; 103, 263−93. doi:  10.1016/j.mcna.2018.10.009
[9] Dehghani R, Rahmani F, Rezaei N. MicroRNA in Alzheimer's disease revisited: implications for major neuropathological mechanisms. Rev Neurosci, 2018; 29, 161−82. doi:  10.1515/revneuro-2017-0042
[10] Putteeraj M, Fairuz YM, Teoh SL. MicroRNA dysregulation in Alzheimer's disease. CNS Neurol Disord Drug Targets, 2017; 16, 1000−9.
[11] Liu CG, Wang JL, Li L, et al. MicroRNA-135a and -200b, potential biomarkers for Alzheimer's disease, regulate β secretase and amyloid precursor protein. Brain Res, 2014; 1583, 55−64. doi:  10.1016/j.brainres.2014.04.026
[12] Yang TT, Liu CG, Gao S, et al. The serum exosome derived microRNA-135a, -193b, and -384 were potential Alzheimer's disease biomarker. Biomed Environ Sci, 2018; 31, 87−96.
[13] Lu Z, Piechowicz M, Qiu S. A simplified method for ultra-low density, long-term primary hippocampal neuron culture. J Vis Exp, 2016; 53797. doi:  10.3791/53797
[14] Wingate R, Kwint M. Imagining the brain cell: the neuron in visual culture. Nat Rev Neurosci, 2006; 7, 745−52.
[15] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001; 25, 402−8. doi:  10.1006/meth.2001.1262
[16] Greening DW, Xu R, Ji H, et al. A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods. Methods Mol Biol, 2015; 1295, 179−209.
[17] Chen W, Yang M, Bai J, et al. Exosome-modified tissue engineered blood vessel for endothelial progenitor cell capture and targeted siRNA delivery. Macromol Biosci, 2018; 18. doi:  10.1002/mabi.201700242
[18] Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol, 2017; 16, 661−76. doi:  10.1016/S1474-4422(17)30159-X
[19] Blennow K, Zetterberg H. The past and the future of Alzheimer's disease fluid biomarkers. J Alzheimers Dis, 2018; 62, 1125−40. doi:  10.3233/JAD-170773
[20] Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiol Dis, 2010; 37, 13−25. doi:  10.1016/j.nbd.2009.07.030
[21] Huang H, Zhu J, Fan L, et al. MicroRNA profiling of exosomes derived from red blood cell units: implications in transfusion-related immunomodulation. Biomed Res Int, 2019; 2019, 2045915.
[22] Theillet G, Martinez J, Steinbrugger C, et al. Comparative study of chikungunya Virus-like particles and pseudotyped-particles used for serological detection of specific immunoglobulin M. Virology, 2019; 529, 195−204. doi:  10.1016/j.virol.2019.01.027
[23] Qian H, Zhao X, Cao P, et al. Structure of the human lipid exporter ABCA1. Cell, 2017; 169, 1228−39. doi:  10.1016/j.cell.2017.05.020
[24] Deng H, Sun C, Sun Y, et al. Lipid, Protein, and MicroRNA Composition Within Mesenchymal Stem Cell-Derived Exosomes. Cell Reprogram, 2018; 20, 178−86. doi:  10.1089/cell.2017.0047
[25] Toh WS, Lai RC, Zhang B, et al. MSC exosome works through a protein-based mechanism of action. Biochem Soc Trans, 2018; 46, 843−53. doi:  10.1042/BST20180079